UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE ~~SECURITIES EXCHANGE ACT OF 1934~~

~~Date~~SECURITIES ofEXCHANGE ~~Report~~ACT ~~(Date~~OF ~~of earliest event reported): December 8, 2025~~1934

Date of Report (Date of earliest event reported): February 5, 2026

OMNICELL, INC.

(Exact name of registrant as specified in its charter)

Delaware

000-33043

94-3166458

(State or other jurisdiction of
incorporation)

(Commission File Number)

(IRS Employer Identification Number)

4220 North Freeway

Fort Worth, TX 76137

(Address of principal executive offices, including zip code)

(877) 415-9990

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, $0.001 par value

OMCL

NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company									☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

~~Emerging growth~~Item 2.02 ~~company~~Results ¨of Operations and Financial Condition.

~~If an~~On ~~emerging~~February 5, ~~growth~~2026, ~~company~~Omnicell, Inc. ~~indicate~~(the by“Company”) ~~check~~issued ~~mark~~a ifpress release announcing its financial results for the ~~registrant~~quarter ~~has~~and ~~elected~~year ~~not~~ended toDecember 31, ~~use~~2025. The full text of the ~~extended~~press ~~transition~~release ~~period~~issued ~~for complying~~in connection with ~~any~~the ~~new~~announcement oris ~~revised~~attached ~~financial~~as ~~accounting~~Exhibit 99.1 ~~standards~~to ~~provided~~this ~~pursuant~~Current toReport ~~Section~~on ~~13(a)~~Form 8-K ofand ~~the~~is ~~Exchange~~incorporated ~~Act~~herein by reference. ¨

The information contained in Item 72.0102 ~~Regulation~~of FDthis ~~Disclosure~~Current Report on Form 8-K and Exhibit 99.1 attached hereto are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

~~On December~~Item ~~8, 2025, Omnicell, Inc~~9.01 ~~(the~~Financial ~~“Company”) issued~~Statements a press release announcing the launch of Omnicell Titan XT, its next generation, automated dispensing system designed to empower autonomous medication management. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and ~~is incorporated herein by reference~~Exhibits.

The information contained in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (~~the “Exchange Act”~~d), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any Company filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Exhibits

Item 9.01. Financial Statements and Exhibits.


Exhibit Number						Exhibit Description
99.1						Press release entitled “Omnicell Announces Fiscal Year and Fourth Quarter 2025 Financial Results ” dated February 5, 2026



104						Cover Page Interactive Data File (embedded within the inline XBRL document)

~~(d) Exhibits.~~SIGNATURES

Exhibit Number		Description of Document
99.1		Press release entitled “Announcing Omnicell Titan XT, the Next Generation, Automated Dispensing System Designed to Empower Autonomous Medication Management” dated December 8, 2025
104		Cover Page Interactive Data File (embedded within the inline XBRL document)

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

SIGNATURES


			OMNICELL, INC.
Date: February 5, 2026			/s/ H. Baird Radford, III
			Baird Radford
			Executive Vice President and Chief Financial Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

	OMNICELL, INC.
Date: December 8, 2025	/s/ H. Baird Radford, III
	H. Baird Radford, III
	Executive Vice President and Chief Financial Officer

Filing Compare · OMNICELL, INC.